Aerie Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Aerie Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).

32 total trials none currently recruiting 32 completed early-phase tilt top decile by trial count

Aerie Pharmaceuticals: 32 sponsored US clinical trials, none currently recruiting.

Aerie Pharmaceuticals sponsors 32 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 11 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 2 trials.

Top-decile sponsor footprint

Aerie Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

32 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

32 total, page 1 of 1

COMPLETED Phase 3

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

NCT05493111
COMPLETED Phase 3

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

NCT05360966
COMPLETED Phase 3

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644
COMPLETED Phase 4

Rocklatan® Evaluation

NCT05283395
COMPLETED Phase 1

Study Evaluating Techniques for Measuring Tear Production

NCT05497479
COMPLETED Phase 2

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT04498182
COMPLETED Phase 2

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

NCT04498169
COMPLETED Phase 1

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

NCT03835884
COMPLETED Phase 2

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
COMPLETED Phase 4

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688
COMPLETED Phase 2

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
COMPLETED Phase 2

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT03233308
COMPLETED Phase 2

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

NCT02874846
COMPLETED Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
COMPLETED Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02558400
COMPLETED Phase 3

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
COMPLETED Phase 1

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

NCT02406287
COMPLETED Phase 3

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
COMPLETED Phase 3

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
COMPLETED Phase 3

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
COMPLETED Phase 2

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

NCT02057575
COMPLETED Phase 1

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

NCT01997879
COMPLETED Phase 2

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

NCT01789736
COMPLETED Phase 2

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002
COMPLETED Phase 2

Study of AR-13324 in Patients With Elevated Intraocular Pressure

NCT01528787
COMPLETED Phase 2

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135
COMPLETED Phase 2

24-hour Efficacy of AR-12286

NCT01330979
COMPLETED Phase 2

AR-12286 in Combination With Latanoprost

NCT01302249
COMPLETED Phase 1

Formulation Comparison in Normal Volunteers

NCT01250197
COMPLETED Phase 2

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

NCT01060579
COMPLETED Phase 2

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
COMPLETED Phase 2

Ocular Hypotensive Efficacy of AR-102

NCT00523250

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 16
Phase 3 9
Phase 4 2

Therapeutic Areas

Dry Eye Disease 2
Primary Open Angle Glaucoma or Ocular Hypertension 2
Open Angle Glaucoma 2
Ocular Hypertension 2
Corneal Edema 1
Normal Volunteers 1
Healthy 1

How the Aerie Pharmaceuticals early-phase archive is shaped

32 indexed studies, none listed as recruiting (0% open); 32 completed (100%).

Phase mix: 11 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Dry Eye Disease (2 trials), 6 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Aerie Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 32 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Aerie Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 010203040 0%5%10%15%20% Total trials Recruiting share Aerie PharmaceuticalsAllina Health SystemArdea BiosciencesHebrew SeniorLifeMiMedx Group10xBio22nd Century Group23andMe3-C Institute for Social Development
Aerie Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aerie Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 32 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aerie Pharmaceuticals page

32 registered trials is a research-attention snapshot, not an endorsement of Aerie Pharmaceuticals or any single study.

  • None of Aerie Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dry Eye Disease is the condition Aerie Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aerie Pharmaceuticals pipeline card: 32 registered trials from official public datasets.Report a data error.